The Korean Journal of Physiology and Pharmacology

The Korean Society of Pharmacology (대한약리학회)
권호 표지
DOI QR코드

DOI QR Code

Repaglinide, but Not Nateglinide Administered Supraspinally and Spinally Exerts an Anti-Diabetic Action in D-Glucose Fed and Streptozotocin-Treated Mouse Models

  • Sim, Yun-Beom (Department of Pharmacology, Institute of Natural Medicine, College of Medicine, Hallym University) ;
  • Park, Soo-Hyun (Department of Pharmacology, Institute of Natural Medicine, College of Medicine, Hallym University) ;
  • Kang, Yu-Jung (Department of Pharmacology, Institute of Natural Medicine, College of Medicine, Hallym University) ;
  • Kim, Sung-Su (Department of Pharmacology, Institute of Natural Medicine, College of Medicine, Hallym University) ;
  • Kim, Chea-Ha (Department of Pharmacology, Institute of Natural Medicine, College of Medicine, Hallym University) ;
  • Kim, Su-Jin (Department of Pharmacology, Institute of Natural Medicine, College of Medicine, Hallym University) ;
  • Lim, Su-Min (Department of Pharmacology, Institute of Natural Medicine, College of Medicine, Hallym University) ;
  • Jung, Jun-Sub (Department of Pharmacology, Institute of Natural Medicine, College of Medicine, Hallym University) ;
  • Ryu, Ohk-Hyun (Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Hallym University) ;
  • Choi, Moon-Gi (Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Hallym University) ;
  • Suh, Hong-Won (Department of Pharmacology, Institute of Natural Medicine, College of Medicine, Hallym University)
  • Received : 2013.03.28
  • Accepted : 2013.10.17
  • Published : 2013.12.30
Download PDF
⟨ Previous Next ⟩

Abstract

We have recently demonstrated that some anti-diabetic drugs such as biguanide and thizolidinediones administered centrally modulate the blood glucose level, suggesting that orally administered anti-diabetic drugs may modulate the blood glucose level by acting on central nervous system. The present study was designed to explore the possible action of another class of anti-diabetic drugs, glinidies, administered centrally on the blood glucose level in ICR mice. Mice were administered intracerebroventricularly (i.c.v.) or intrathecally (i.t.) with 5 to $30{\mu}g$ of repaglinide or nateglinide in D-glucose-fed and streptozotocin (STZ)-treated models. We found that i.c.v. or i.t. injection with repaglinide dose-dependently attenuated the blood glucose level in D-glucose-fed model, whereas i.c.v. or i.t. injection with nateglinide showed no modulatory action on the blood glucose level in D-glucose-fed model. Furthermore, the effect of repaglinide administered i.c.v. or i.t. on the blood glucose level in STZ-treated model was studied. We found that repaglinide administered i.c.v. slightly enhanced the blood glucose level in STZ-treated model. On the other hand, i.t. injection with repaglinide attenuated the blood glucose level in STZ-treated model. The plasma insulin level was enhanced by repaglinide in D-glucose-fed model, but repaglinide did not affect the plasma insulin level in STZ-treated model. In addition, nateglinide did not alter the plasma insulin level in both D-glucose-fed and STZ-treated models. These results suggest that the anti-diabetic action of repaglinide appears to be, at least, mediated via the brain and the spinal cord as revealed in both D-glucose fed and STZ-treated models.

Keywords

References

  1. Cheng AY, Fantus IG. Oral antihyperglycemic therapy for type 2 diabetes mellitus. CMAJ. 2005;172:213-226. https://doi.org/10.1503/cmaj.1031414
  2. Farret A, Lugo-Garcia L, Galtier F, Gross R, Petit P. Pharmacological interventions that directly stimulate or modulate insulin secretion from pancreatic beta-cell: implications for the treatment of type 2 diabetes. Fundam Clin Pharmacol. 2005; 19:647-656. https://doi.org/10.1111/j.1472-8206.2005.00375.x
  3. Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care. 2000;23:1660-1665. https://doi.org/10.2337/diacare.23.11.1660
  4. Perfetti R, Barnett PS, Mathur R, Egan JM. Novel therapeutic strategies for the treatment of type 2 diabetes. Diabetes Metab Rev. 1998;14:207-225. https://doi.org/10.1002/(SICI)1099-0895(1998090)14:3<207::AID-DMR214>3.0.CO;2-J
  5. Sunaga Y, Gonoi T, Shibasaki T, Ichikawa K, Kusama H, Yano H, Seino S. The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide. Eur J Pharmacol. 2001;431:119-125. https://doi.org/10.1016/S0014-2999(01)01412-1
  6. Bokvist K, Hoy M, Buschard K, Holst JJ, Thomsen MK, Gromada J. Selectivity of prandial glucose regulators: nateglinide, but not repaglinide, accelerates exocytosis in rat pancreatic A-cells. Eur J Pharmacol. 1999;386:105-111. https://doi.org/10.1016/S0014-2999(99)00754-2
  7. Bryan J, Crane A, Vila-Carriles WH, Babenko AP, Aguilar- Bryan L. Insulin secretagogues, sulfonylurea receptors and K(ATP) channels. Curr Pharm Des. 2005;11:2699-2716. https://doi.org/10.2174/1381612054546879
  8. Gribble FM, Reimann F. Differential selectivity of insulin secretagogues: mechanisms, clinical implications, and drug interactions. J Diabetes Complications. 2003;17(2 Suppl):11-15.
  9. Henquin JC. Pathways in beta-cell stimulus-secretion coupling as targets for therapeutic insulin secretagogues. Diabetes. 2004;53 Suppl 3:S48-58. https://doi.org/10.2337/diabetes.53.suppl_3.S48
  10. Islam MS. The ryanodine receptor calcium channel of betacells: molecular regulation and physiological significance. Diabetes. 2002;51:1299-1309. https://doi.org/10.2337/diabetes.51.5.1299
  11. Benzo CA. Minireview. The hypothalamus and blood glucose regulation. Life Sci. 1983;32:2509-2515. https://doi.org/10.1016/0024-3205(83)90231-X
  12. Ohnuma H, Yamatani K, Igarashi M, Sugiyama K, Manaka H, Tominaga M, Sasaki H. Intracerebroventricular injection of methylatropine suppresses insulin response to oral glucose load in rats. J Auton Nerv Syst. 1996;57:43-48. https://doi.org/10.1016/0165-1838(95)00101-8
  13. Petit F, Jarrous A, Dickinson RD, Molina PE, Abumrad NN, Lang CH. Contribution of central and peripheral adrenergic stimulation to IL-1 alpha-mediated glucoregulation. Am J Physiol. 1994;267:E49-56.
  14. Sala F, Menna G, Bricolo A, Young W. Role of glycemia in acute spinal cord injury. Data from a rat experimental model and clinical experience. Ann N Y Acad Sci. 1999;890:133-154. https://doi.org/10.1111/j.1749-6632.1999.tb07989.x
  15. Ritter S, Bugarith K, Dinh TT. Immunotoxic destruction of distinct catecholamine subgroups produces selective impairment of glucoregulatory responses and neuronal activation. J Comp Neurol. 2001;432:197-216. https://doi.org/10.1002/cne.1097
  16. Sim YB, Park SH, Kang YJ, Jung JS, Ryu OH, Choi MG, Suh HW. Interleukin-1$\beta$ (IL-1$\beta$) increases pain behavior and the blood glucose level: possible involvement of sympathetic nervous system. Pharmacol Biochem Behav. 2012;102:170-176. https://doi.org/10.1016/j.pbb.2012.04.006
  17. Sim YB, Park SH, Kang YJ, Jung JS, Ryu OH, Choi MG, Suh HW. Various pain stimulations cause an increase of the blood glucose level. Animal Cells and Systems. 2012;16:385-390. https://doi.org/10.1080/19768354.2012.696554
  18. Sim YB, Park SH, Kang YJ, Kim SS, Kim CH, Kim SJ, Jung JS, Ryu OH, Choi MG, Suh HW. Central anti-diabetic action of biguanide and thizolidinediones in D-glucose fed and streptozotocin- treated mouse models. Neurosci Lett. 2012;528:73-77. https://doi.org/10.1016/j.neulet.2012.08.038
  19. Hylden JL, Wilcox GL. Intrathecal substance P elicits a caudally-directed biting and scratching behavior in mice. Brain Res. 1981;217:212-215. https://doi.org/10.1016/0006-8993(81)90203-1
  20. Haley TJ. Pharmacological effects produced by intracerebral administration of drugs of unrelated structure to conscious mice. Arch Int Pharmacodyn Ther. 1957;110:239-244.
  21. Zhang Y, Zhou J, Corll C, Porter JR, Martin RJ, Roane DS. Evidence for hypothalamic K+(ATP) channels in the modulation of glucose homeostasis. Eur J Pharmacol. 2004;492:71-79. https://doi.org/10.1016/j.ejphar.2004.03.040
  22. Arison RN, Ciaccio EI, Glitzer MS, Cassaro JA, Pruss MP. Light and electron microscopy of lesions in rats rendered diabetic with streptozotocin. Diabetes. 1967;16:51-56. https://doi.org/10.2337/diab.16.1.51
  23. Mansford KR, Opie L. Comparison of metabolic abnormalities in diabetes mellitus induced by streptozotocin or by alloxan. Lancet. 1968;1:670-671.

Cited by

  1. Effects of nateglinide and repaglinide administered intracerebroventricularly on the CA3 hippocampal neuronal cell death and hyperglycemia induced by kainic acid in mice vol.104, pp.None, 2014, https://doi.org/10.1016/j.brainresbull.2014.02.003
  2. The modulatory roles of oxyntomodulin and glucagon-like peptide 1 administered spinally in the regulation of the blood glucose level vol.11, pp.1, 2013, https://doi.org/10.1134/s1819712416040115
  3. Spinal β-adrenergic receptors’ activation increases the blood glucose level in mice vol.21, pp.4, 2013, https://doi.org/10.1080/19768354.2017.1345788